These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Comparison of the reactogenicity and immunogenicity of a combined diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated polio (DTPa-HBV-IPV) vaccine, mixed with the Haemophilus influenzae type b (Hib) conjugate vaccine and administered as a single injection, with the DTPa-IPV/Hib and hepatitis B vaccines administered in two simultaneous injections to infants at 2, 4 and 6 months of age. Arístegui J, Dal-Ré R, Díez-Delgado J, Marés J, Casanovas JM, García-Corbeira P, De Frutos E, Van Esso D, Verdaguer J, De la Flor J, Moraga F, Boceta R, García-Martínez JA. Vaccine; 2003 Sep 08; 21(25-26):3593-600. PubMed ID: 12922087 [Abstract] [Full Text] [Related]
9. Immunogenicity and safety of a new hexavalent vaccine (DTaP5-IPV-HB-Hib) administered in a mixed primary series schedule with a pentavalent vaccine (DTaP5-IPV-Hib). Martinón-Torres F, Boisnard F, Thomas S, Sadorge C, Borrow R, PRI02C study group. Vaccine; 2017 Jun 27; 35(30):3764-3772. PubMed ID: 28583305 [Abstract] [Full Text] [Related]
15. Immunogenicity and safety of a combined DTPa-IPV/Hib vaccine administered as a three-dose primary vaccination course in healthy Korean infants: phase III, randomized study. Kim KH, Kim CS, Kim HM, Kim JD, Ma SH, Kim DH, Hwang PH, Han JW, Lee TJ, Kim JH, Karkada N, Mesaros N, Sohn WY, Kim JH. Hum Vaccin Immunother; 2019 Jun 27; 15(2):317-326. PubMed ID: 30431387 [Abstract] [Full Text] [Related]
16. Immunogenicity and safety of primary and booster vaccination with 2 investigational formulations of diphtheria, tetanus and Haemophilus influenzae type b antigens in a hexavalent DTPa-HBV-IPV/Hib combination vaccine in comparison with the licensed Infanrix hexa. Vesikari T, Rivera L, Korhonen T, Ahonen A, Cheuvart B, Hezareh M, Janssens W, Mesaros N. Hum Vaccin Immunother; 2017 Jul 03; 13(7):1505-1515. PubMed ID: 28340322 [Abstract] [Full Text] [Related]
18. A Phase III randomized, double-blind, clinical trial of an investigational hexavalent vaccine given at 2, 4, and 11-12 months. Silfverdal SA, Icardi G, Vesikari T, Flores SA, Pagnoni MF, Xu J, Liu GF, Stek JE, Boisnard F, Thomas S, Ziani E, Lee AW. Vaccine; 2016 Jul 19; 34(33):3810-6. PubMed ID: 27288217 [Abstract] [Full Text] [Related]
19. Sequential inactivated (IPV) and live oral (OPV) poliovirus vaccines for preventing poliomyelitis. Ciapponi A, Bardach A, Rey Ares L, Glujovsky D, Cafferata ML, Cesaroni S, Bhatti A. Cochrane Database Syst Rev; 2019 Dec 05; 12(12):CD011260. PubMed ID: 31801180 [Abstract] [Full Text] [Related]
20. Immunogenicity and reactogenicity of primary immunization with a hexavalent diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio-Haemophilus influenzae type B vaccine coadministered with two doses of a meningococcal C-tetanus toxoid conjugate vaccine. Tejedor JC, Moro M, Ruiz-Contreras J, Castro J, Gómez-Campderá JA, Navarro ML, Merino JM, Martín-Ancel A, Roca J, García-del-Río M, Jurado A, Díez-Delgado FJ, Omeñaca F, García-Sicilia J, Boceta R, García-Corbeira P, Jacquet JM, Collard A, Schuerman L, Spanish DTaP-HBV-IPV-097 Study Group. Pediatr Infect Dis J; 2006 Aug 05; 25(8):713-20. PubMed ID: 16874171 [Abstract] [Full Text] [Related] Page: [Next] [New Search]